LOGPROSTYLE INC

Logprostyle falls 2.13% as a $15M biotech stocks’ 200‑day SMA stays above price, revealing operational gaps, capital limits and a steep month‑end slide.

Logprostyle (LGPS) slumps 20% from last month, trading thinly below its 200‑day SMA and 52‑week low—investors face a systemic risk and urgent need for a turnaround plan.